Not Yet Recruiting PHASE1 INTERVENTIONAL 2-arm
NCT06798519
Relative Bioavailability Study of HNC364 Injectable Suspension
A Relative Bioavailability Study of HNC364 Following Intramuscular Injections Vs. AZILECT® (Rasagiline Tablet) Following Oral Administration At the Steady-State in Healthy Adult Subjects
Sponsor: Guangzhou Henovcom Bioscience Co. Ltd.
Conditions
Parkinson's Disease (PD)
Interventions
HNC364 Injectable Suspension Rasagiline Tablets
Updated 1 time since 2025 Last updated: Jan 22, 2025 Started: May 1, 2025 Primary completion: May 31, 2026 Completion: Jun 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE1 trial investigates Parkinson's Disease (PD) and is currently actively recruiting participants. Guangzhou Henovcom Bioscience Co. Ltd. leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Guangzhou Henovcom Bioscience Co. Ltd.
Data source: Guangzhou Henovcom Bioscience Co. Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.